> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regeneron’s Eylea OK’d for Diabetic Retinopathy
- URL: https://www.fdaweb.com/regenerons-eylea-okd-for-diabetic-retinopathy/
- Published: 2019-05-13T12:00:00.000Z
- Updated: 2026-09-15T01:26:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144094

FDA has approved Regeneron Pharmaceuticals’ Eylea (aflibercept) injection to treat all stages of diabetic retinopathy. Approval was based on data from the PANORAMA trial which showed that “20% of untreated patients developed proliferative diabetic eye disease, and Eylea reduced this risk by 85% to 88% when administered using an every 16-week or eight-week dosing regimen, respectively,” the company says.

It describes Eylea as a VEGF inhibitor designed to block the growth of new blood vessels and decrease the ability of fluid to pass through blood vessels (vascular permeability) in the eye by blocking VEGF-A and placental growth factor, two growth factors involved in angiogenesis. Previously, the drug was approved for treating patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.